Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

For many of us, there’s no avoiding the workday, but making your desk space feel warm and true to your personality can ...

Citi head of US equity strategy Scott Chronert joins Market Domination hosts Julie Hyman and Josh Lipton to discuss Monday's "Magnificent Seven" rally in the context of the recent tech trade ...

During the recent period between index selection dates, U.S. stock markets faced a steep decline, with the S&P 500 falling 8.6% and the Nasdaq Composite dropping 11.9%. The BUZZ NextGen AI U.S ...

The FlexiSpot E7 is the best standing desk overall - built from durable materials, we found it easy to assemble, stable in use, and quiet in operation, making it a good choice for shared ...